Acer Therapeutics (ACER)
(Delayed Data from OTC)
$0.66 USD
0.00 (0.00%)
Updated Nov 20, 2023 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Acer Therapeutics Inc. [ACER]
Reports for Purchase
Showing records 81 - 100 ( 213 total )
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Conclusive (and Inclusive) Quarterly Update For 3Q20
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
3Q20 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
3Q20: Obtains ACER-001 Regulatory Clarity, Evaluating Emetine Potential
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
EVENT: COVID-19 Therapeutics in Development: Beyond Gilead, Regeneron and Lilly
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
We are updating coverage of our Healthcare sector to better allocate our research resources in
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Pipeline Poised to Yield Multiple Catalysts; 2Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
ACER 2Q20: Several Near Term Catalysts, ACER-001 Is Increasingly Differentiated
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Catalyst Rich, Notable Takeaway Messages from Recent Management Meetings
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
ACER-001 Food Effect Study Could Have Key Implications; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
ACER-001 Performs Optimally as Preprandial Dose, Confers Likely Advantage
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
001 Drives Valuation, Other Assets Have Potential - Transferring Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
1Q20 - Nature''s Answer for an Anti-COVID-19 Therapy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
1Q20 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Emetine Repositioning for COVID-19 Infection; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R